Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance

被引:9
|
作者
Babrzadeh, Farbod [1 ]
Varghese, Vici [2 ]
Pacold, Mary
Liu, Tommy F.
Nyren, Pal [3 ]
Schiffer, Celia [4 ]
Fessel, W. Jeffrey [5 ]
Shafer, Robert W.
机构
[1] Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Div Infect Dis, Dept Med, Stanford, CA 94305 USA
[3] KTH, AlbaNova Univ Ctr, Dept Biotechnol, Stockholm, Sweden
[4] Univ Massachusetts, Med Ctr, Dept Biochem, Worcester, MA USA
[5] Kaiser Permanente Med Care Program No Calif, Clin Trials Unit, San Francisco, CA USA
关键词
drug resistance; deep sequencing; minority variants; Sanger sequencing; ATAZANAVIR;
D O I
10.1093/jac/dks409
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs. We performed deep sequencing of plasma virus samples from nine patients with high-level genotypic and/or phenotypic resistance to all licensed PIs. The nine virus samples had a median of 12 PI resistance mutations by direct PCR Sanger sequencing. For each of the nine virus samples, deep sequencing showed that each of the individual viruses within a sample contained nearly all of the mutations detected by Sanger sequencing. Indeed, a median of 94.9 of deep sequence reads had each of the PI resistance mutations present as a single chromatographic peak in the Sanger sequence. A median of 5.0 of reads had all but one of the Sanger mutations that were not part of an electrophoretic mixture. The collinearity of PI resistance mutations in the nine virus samples demonstrated that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes. We hypothesize that the marked collinearity of PI resistance mutations in pan-PI-resistant virus populations results from the unique requirements for multi-PI resistance and the extensive cross-resistance conferred by many of the accessory PI resistance mutations.
引用
收藏
页码:414 / 418
页数:5
相关论文
共 50 条
  • [31] Design of a folding inhibitor of the HIV-1 protease
    Tiana, G
    Broglia, RA
    Sutto, L
    Provasi, D
    MOLECULAR SIMULATION, 2005, 31 (11) : 765 - 771
  • [32] Atazanavir: a novel HIV-1 protease inhibitor
    Piliero, PJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (09) : 1295 - 1301
  • [33] Interdependence of Inhibitor Recognition in HIV-1 Protease
    Paulsen, Janet L.
    Leidner, Florian
    Ragland, Debra A.
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2017, 13 (05) : 2300 - 2309
  • [34] The HIV-1 protease inhibitor saquinavir is a radiosensitizer
    Himmelsbach, J
    McBride, WH
    Pajonk, F
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 : 37 - 37
  • [35] The binding energy of HIV-1 protease inhibitor
    Ka, J
    Park, SH
    Kim, H
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 1996, 17 (01) : 19 - 24
  • [36] THE STRUCTURES OF INHIBITOR COMPLEXES OF HIV-1 PROTEASE
    WLODAWER, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 200 : 82 - MEDI
  • [37] Role of HIV-1 protease residues 71 and 89 in protease inhibitor resistance of subtype G viruses
    Gonzalez, LMF
    Van Laethem, K
    Abecasis, AB
    Soares, EAJM
    Deforche, K
    Vandamme, AM
    Camacho, R
    Soares, MA
    ANTIVIRAL THERAPY, 2005, 10 : S112 - S112
  • [38] Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance
    Su, Chinh Tran-To
    Ling, Wei-Li
    Lua, Wai-Heng
    Haw, Yu-Xuan
    Gan, Samuel Ken-En
    BMC BIOINFORMATICS, 2016, 17
  • [39] Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance
    Chinh Tran-To Su
    Wei-Li Ling
    Wai-Heng Lua
    Yu-Xuan Haw
    Samuel Ken-En Gan
    BMC Bioinformatics, 17
  • [40] Analyses of accessory mutations in HIV-1 protease reveal interdependent mechanisms of resistance
    Ragland, D. A.
    Nalam, M. N. L.
    Ozen, A.
    Cai, Y.
    Cao, H.
    Schiffer, C. A.
    ANTIVIRAL THERAPY, 2014, 19 : A155 - A155